ASCO

Utilizing Chemotherapy to Treat Lung Cancer

By Benjamin P. Levy, MD

ASCO, ASCO 2016 – Lung Cancer

Benjamin P. Levy, MD, talks about the role chemotherapy currently plays in an arena where the cancer care team is emphasizing genomic profiling and targeted therapies to treat patients with lung cancer.

A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

An open-label phase 2 trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928)

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Bayesian randomized trial comparing intensity-modulated radiation therapy versus passively scattered proton therapy for locally advanced non–small-cell lung cancer

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

E1505: Adjuvant chemotherapy ± bevacizumab for early stage NSCLC—outcomes based on chemotherapy subsets

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Page 4 of 19

1
2
3
4
5
6
7